Answers are grounded in this paper and cite their sources.
Transgenic model demonstrates reversible protein degradation of SHP-1 in T cells, indicating role in immune response mechanisms.
Description Transgenic and knockout mouse models have significantly contributed to the progress on the in vivo understanding of molecules and pathways underlying human health. However, once a gene has been targeted, the genetic change is permanent. Approaches that specifically and reversibly target the protein rather than the gene, in the cell lineage of choice, would therefore be a great resource. Here, we generated an in vivo method that can achieve Inducible and Resersible In vivo Protein degradation (IRIP) by combining the power of two approaches: a recently described Auxin-induced degron (AID) system for reversible protein degradation and lineage-specific targeting via existing Cre-lines. Specifically as a proof of principle, we engineered a mouse model to achieve T cell-specific IRIP of SHP-1 by generating and combining two novel mouse strains; (1) a strain that expresses the Auxin-responsive TIR1 protein in a Cre-dependent manner allowing for cell lineage-specific expression using existing Cre strains, and (2) a strain that tags endogenous SHP-1 with an AID-targeting sequence. Functional assays have demonstrated the specificity of the AID system in vivo allowing for new insights into the role of SHP-1 during an immune response. Moreover, we believe that the development of this murine model of inducible and reversible protein degradation (IRIP) created a new tool for in vivo studies with significant benefit for the larger research community.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: